Almost normal cognitive function in patients during therapy for childhood acute lymphoblastic leukemia without cranial irradiation according to ALL-BFM 95 and COALL 06-97 protocols: results of an Austrian-German multicenter longitudinal study and implications for follow-up

Paul Krappmann; Marios Paulides; Wolfgang Stöhr; Edith Ittner; Bernhard Plattig; Petra Nickel; Herwig Lackner; Martin Schrappe; Gritta Janka; Jörn D Beck; Thorsten Langer

doi:10.1080/08880010601123281

Almost normal cognitive function in patients during therapy for childhood acute lymphoblastic leukemia without cranial irradiation according to ALL-BFM 95 and COALL 06-97 protocols: results of an Austrian-German multicenter longitudinal study and implications for follow-up

Pediatr Hematol Oncol. 2007 Mar;24(2):101-9. doi: 10.1080/08880010601123281.

Authors

Paul Krappmann¹, Marios Paulides, Wolfgang Stöhr, Edith Ittner, Bernhard Plattig, Petra Nickel, Herwig Lackner, Martin Schrappe, Gritta Janka, Jörn D Beck, Thorsten Langer

Affiliation

¹ Department of Pediatric Hematology and Oncology, University Hospital for Children and Adolescents. Erlangen. Germany.

PMID: 17454775
DOI: 10.1080/08880010601123281

Abstract

In a multicenter study the authors prospectively investigated neurocognitive function in childhood ALL patients. Sixty-six patients (mean age at diagnosis 7.9 +/- 3.6 years, 34 female), treated with repeated intrathecal and systemical methotrexate administrations without cranial irradiation, underwent psychometric testing for intelligence, concentration, and visual-motor integration postdiagnosis and after reinduction therapy. Although there was a statistically significant decline of intellectual function after reinduction therapy for younger patients and girls (IQ scores still within normative data range), there were no differences in visual-motor performance and concentration over the time of induction therapy. Thus, neurocognitive examination should focus on younger ALL patients and girls.

Publication types

Multicenter Study
Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Asparaginase / adverse effects
Asparaginase / therapeutic use
Child
Child, Preschool
Cognition Disorders / chemically induced*
Cognition Disorders / physiopathology
Cranial Irradiation*
Cyclophosphamide / adverse effects
Cyclophosphamide / therapeutic use
Cytarabine / adverse effects
Cytarabine / therapeutic use
Daunorubicin / adverse effects
Daunorubicin / therapeutic use
Female
Follow-Up Studies
Humans
Injections, Spinal
Intelligence Tests
Longitudinal Studies
Male
Mercaptopurine / adverse effects
Mercaptopurine / therapeutic use
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
Prednisolone / adverse effects
Prednisolone / therapeutic use
Prospective Studies
Psychomotor Performance / drug effects
Psychomotor Performance / physiology
Risk Factors
Vincristine / adverse effects
Vincristine / therapeutic use

Substances

Cytarabine
Vincristine
Cyclophosphamide
Prednisolone
Mercaptopurine
Asparaginase
Daunorubicin

Supplementary concepts

ALL-BFM-95 protocol